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Abstract The predictive value of clinical and platelet
kinetic parameters for treatment outcome in idiopathic
thrombocytopenic purpura (ITP) was investigated in 75
patients with platelets ≤20×109/L. The platelet kinetic studies
showed that the platelet production rate (PPR) was decreased
(<100×109/day), normal, or increased (>355×109/day) in
33%, 48%, and 19% of patients, respectively. All patients
started with prednisone at diagnosis (1 mg/kg/day). Initial
complete and partial response (CR/PR) rate was 84% and a
durable CR/PR (≥6 months without treatment) was attained
in 44% of the patients. Durable CR/PR was noticed in 64%
of the patients with decreased PPR during a median follow-
up time without treatment of 81 (range 18–92) months,
compared to 34% of the patients with normal or increased
PPR during a median follow-up time without treatment of
141 (range 10–284) months (p=0.03). Splenectomy was
performed in 32% of patients with decreased PPR and in
62% of patients with normal or increased PPR (p=0.03). In
conclusion, ITP patients with suppressed PPR have a
significant higher durable CR/PR rate to prednisone therapy
and are less frequently exposed to splenectomy than those
with a normal or increased PPR.
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Introduction
Thrombocytopenia in idiopathic thrombocytopenic purpura
(ITP) is predominantly caused by autoantibodies that
recognize antigens on platelets and megakaryocytes result-
ing in accelerated platelet destruction and decreased platelet
production rate (PPR) [1, 2]. Premature cell death of
megakaryocytes plays an important role in the reduced
platelet production [3]. However, easily applicable tests that
can make a distinction between a reduced platelet half life
and a reduced PPR are lacking. Circulating thrombopoietin
distinguishes between disorders of platelet destruction and
production [4] but has no discrimitive value within a group
of ITP patients. Platelet glycocalicin, the soluble outer
fragment of the α-chain of platelet glycoprotein Ib, may
distinguish between thrombocytopenia due to reduced
production or increased destruction [5], but its diagnostic
value in patients with ITP is not well defined. In the
absence of simple tests, platelet kinetic studies are still the
only method to determine the relative contribution of
increased peripheral platelet destruction and decreased
production [6]. Many studies have been performed to
analyze the predictive value of thrombokinetic parameters
for the response to treatment in ITP. Most of these studies
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have focused on splenectomy. Although individual studies
have reported a predictive value for the site of platelet
sequestration for the response to splenectomy, a recent
systemic review did not support this notion [7]. The
predictive value of the PPR has not been extensively
investigated. Siegel et al. [8] showed that an increased PPR
in conjunction with a short platelet survival correlated with
a favorable response to splenectomy, while patients with a
reduced PPR and a moderately reduced survival demon-
strated a poor outcome following splenectomy. In keeping
with these findings are platelet kinetic studies using
radioactive indium (111In), which have shown that splenec-
tomy improves the platelet counts predominantly by
increasing platelet survival [9, 10]. In these studies [9,
10], prednisone primarily affected the platelet production,
which contradicted earlier radiolabeled platelet studies
using chromium-51 (51Cr), suggesting that successful
response to prednisone was caused by an increase in
platelet survival [11]. In the present study, we investigated
the predictive value of thrombokinetic and clinical parameters
in 75 adult patients with severe ITP. The results demonstrate
that patients with a decreased PPR have a significantly higher
durable complete and partial response (CR/PR) to prednisone,
and subsequently are less frequently exposed to splenectomy
than patients with a normal or increased PPR.
Materials and methods
Patients
Seventy-five untreated adult patients with severe ITP were
investigated after informed consent was obtained. The
institutional review board of the University Hospital
Groningen approved the study protocol. The diagnosis
was made according to the guidelines on ITP from the
American Society of Hematology [12]. This requires that
thrombocytopenia in an otherwise healthy person remains
of undetermined etiology after history, physical examina-
tion, complete blood count, and examination of the
peripheral blood smear. Patients with associated systemic
diseases, including human immunodeficiency virus infection,
were excluded. Consecutive patients with a platelet count
≤20×109/L were enrolled from 1 January 1977 until 1
November 2005. Patients who were receiving treatment for
ITP, including glucocorticoids and intravenous immunoglo-
bulins, at the time of radiolabeled studies and patients who
underwent platelet kinetic studies during the course of the
disease or at the time of relapse were also not included.
Patients with a complete or partial response (PR) to
prednisone needed to be at least 6 months without
prednisone or other treatment for ITP at the moment of
evaluation.
Treatment strategy and definitions
Treatment with prednisone (1 mg kg−1 day−1) was started at
a platelet count ≤20×109/L irrespective of the presence of
bleeding. The protocol prescribed that splenectomy should
be performed if there was no initial response to prednisone
after 4–6 weeks of therapy, when relapse of thrombocyto-
penia occurred after tapering prednisone, or in the case of a
severe hemorrhagic diathesis.
A patient was considered to have a complete response
(CR) if the platelet count increased to ≥150×109/L, and a PR
when the platelet count varied between 30 to 150×109/L.
No response (NR) was defined if the platelet count
remained unchanged or increased to less than 30×109/L.
Additionally, a distinction between initial and durable CR
and PR was made. A CR or PR was considered durable if it
persisted for more than 6 months after cessation of therapy.
Initial PR or CR to prednisone or splenectomy was defined
as rise in the platelet count ≥30 and ≥150×109/L,
respectively, within 3 months after initiating therapy.
Patients who had an initial response to prednisone but
relapsed during tapering of prednisone were considered as
nonresponders. The rate and duration of tapering was left to
the discretion of the treating physician.
The observation period (defined as follow-up time)
started on the day of initial diagnosis and finished on
January 1, 2006, or when a patient died (due to any cause).
Long-term clinical follow-up data were obtained in 72
patients. Three patients were lost during follow up. The
relapse-free follow-up time after a certain treatment is
defined as months between the date of reaching initial CR
or PR to this treatment and the date of relapse defined by
platelets ≤30×109/L, splenectomy, death, or the final date
of the study. Time to splenectomy indicates months
between the date of diagnosis and the date of splenectomy.
Time to splenectomy failure is defined as months between
the date of splenectomy and a decrease in the platelet count
to ≤30×109/L.
Platelet kinetic studies
111In-tropolonate was used for labeling [concentration
25 μg/mL, activity 37 MBq Indium-111 at calibration time
(Mallinckrodt Medical, Petten, The Netherlands, BV)].
Intravenous blood was collected in polypropylene syringes
(Becton and Dickinson, Mountain View, CA, USA), and
the labeling procedure was performed in polypropylene
tubes (Falcon 2070, Becton and Dickinson). Acid citrate
dextrose was used as anticoagulant, according to the
recommendations of the National Institute of Health (22 g
trisodium citrate, 8 g citric acid, and 25 g dextrose per liter).
Labeling was performed following the recommendations
of the International Committee on Standardization in
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Hematology [13]. Briefly, autologous blood was collected
in acid-citrate-dextrose solution and centrifuged at 200 g.
Platelet-rich plasma was harvested and acidified (pH 6.5)
and the platelets were pelleted by centrifugation. The pellet
was resuspended in autologous platelet-poor plasma and
labeled with 10 MBq 111In-tropolonate. After labeling
efficiency was established (usually >90%), a dose of
approximately 7 MBq radiolabeled platelets was injected.
Before injection, the platelet suspension was evaluated for
lymphocyte and red cell contamination.
Initial platelet recovery, mean platelet lifespan, and PPR
were calculated in whole blood samples taken at intervals
of 1, 3, and 5 h after injection and twice a day for 4 days
thereafter. Additional blood samples were drawn on the first
day if reduced mean platelet lifespan was expected.
Extrapolation of the platelet survival curve to time zero
was used in the determination of platelet recovery. The
initial platelet recovery is defined as the percentage of
platelets circulating in the blood immediately after injec-
tion. Mean platelet lifespan was calculated using the
multiple hit model, following the recommendations of the
International Committee of Standardization in Hematology
[13]. Blood volume in liters was estimated from height and
weight [14]. PPR was calculated from mean platelet
lifespan, platelet count, and initial platelet recovery follow-
ing the description of Harker and Finch [15] and multiplied
by the blood volume, and therefore expressed as platelets/
day. At stable platelet counts, platelet turnover (i.e., the rate
of platelet destruction) equals PPR. The PPR can therefore
be defined as the number of platelets entering the
circulation to maintain the platelet count. This is not
necessarily identical to the real platelet production because
production in the bone marrow without release of platelets
into the circulation may occur. Normal values, expressed as
median (range), are a mean platelet lifespan of 9.2 (7.4–11)
days, a PPR of 223 (100–355)×109/day, and an initial
platelet recovery of 60 (45–88) percent. These values were
obtained from platelet kinetic studies in 11 healthy
volunteers, who were recruited from laboratory personnel
and hospital staff [16]. PPR was defined as decreased when
<100×109/day, and increased when >355×109/day.
Organ uptake measurements
Platelet destruction took place in the spleen or liver or both,
or diffusely in the reticuloendothelial system. Hepatic and
splenic uptakes were measured with a large-field-of-view
gamma camera interfaced with a computer (ICON, Siemens,
Chicago, IL, USA). Immediately after injection of the
labeled platelets, 60 1-min frames were recorded in the
posterior position. Dynamic investigation was followed by
5-min static acquisition in both anterior and posterior
positions. Twice a day, these views were repeated and blood
samples were taken to calculate absolute uptake, platelet
activity in liver and spleen [17], and the geometric mean of
the liver and spleen.
In normal subjects, hepatic and splenic uptake remains
relatively constant during the 5 days. Thus, apart from the
pooling phenomenon in the first hour after injection,
increased splenic or hepatic uptake during the next few
days indicates increased platelet destruction. In patients
with nonsplenic sequestration, platelets are destroyed in the
liver or diffusely in the reticuloendothelial system.
Statistical analysis
Continuous data are reported as median (range). Statistical
comparisons were performed using the Mann Whitney U
test, Chi-square, and Fisher’s exact test. Correlation was
assessed with the Spearman’s rank correlation procedure.
The Kaplan–Meier method was used to calculate relapse-free
survival (RFS) curves. Statistical significance of differences
between the groups was assessed using the log-rank test.
Findings were considered statistically significant at the
p<0.05 level, and all tests were two-sided.
Results
Seventy-five patients with severe ITP (platelet count ≤20×
109/L) were evaluated. Patient characteristics are shown in
Table 1. Platelet kinetic studies were performed in all
studied patients. Total follow-up time after diagnosis was a
median of 132 (13–348) months. Seventy (93%) patients
had a follow up of more than 3 years. Sixteen patients
(21%) died during follow up at a median of 81 (13–293)
months after diagnosis. Median age at the time of death was
81 (33–95) years. Fourteen patients died of causes
unrelated to ITP or treatment for ITP. The causes were
mainly cardiopulmonary-related in 12 patients, while two
patients (at age of 39 and 40 years) died of disseminated
malignancy that developed years after the diagnosis of ITP
was established. Of these 14 patients, nine patients had
reached a durable CR/PR to prednisone, two patients had a
durable CR to splenectomy and two patients were refrac-
tory to prednisone and splenectomy but reached a CR to an
alternative therapy, and one patient had NR to prednisone
and splenectomy and was not treated afterwards. Two
patients died at the ages of 33 and 70 years of uncontrolled
bleeding during severe thrombocytopenia due to refractory
ITP. Three patients were lost to follow-up 27, 60, and
72 months after diagnosis. Of these three patients, two had
a durable CR after splenectomy and one patient had NR to
prednisone but had stable platelet counts ≤30×109/L
without bleeding complications with no therapy and refused
splenectomy.
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Response to treatment
All 75 patients were treated with prednisone; 63 (84%) had
an initial CR or PR to prednisone whereas 33 patients
(44%) had a durable CR/PR to prednisone therapy.
Following discontinuation of prednisone, these patients
were relapse-free during a median follow-up time of 99
(10–284) months. Kaplan Meier analysis for RFS following
prednisolone therapy is shown in Fig. 1. RFS estimate was
44% [95% CI (32%–56%)] and the median RFS time was
38 [95% CI (0–101)] months (mean 135 [95% CI (102–
168)] months). Patients who reached a durable response to
prednisone were also not treated with additional medica-
tions. Eleven patients did not respond to prednisone at all
and underwent splenectomy. One additional nonresponding
patient refused splenectomy and was treated for a longer
period (12 months) with low-dose prednisone. Thirty
patients relapsed during tapering of prednisone therapy.
Two of these patients refused splenectomy and 28 patients
were subsequently splenectomized. Characteristics of the
patients according to durable CR/PR and NR to prednisone
therapy are shown in Table 2. With regard to most
characteristics, no significant differences were observed
between the two groups except for the relative number of
patients with a decreased PPR, which was significantly
higher in the group with a durable CR/PR (p=0.03).
Of the patients (n=25) with a decreased PPR (<100×
109/day), 16 (64%) reached a durable CR/PR to prednisone,
compared to 17 (34%) of the patients (n=50) with a normal
or increased PPR (≥100×109/day) (p=0.03). Following
discontinuation of prednisone, the patient groups were
relapse-free during a median follow up of 81 (18–192)
and 141 (10–284) months, respectively. Figure 2 shows
Kaplan Meier estimates of RFS for patients with decreased
or normal/increased PPR following prednisone therapy. For
the patients with a decreased PPR, RFS estimate was 64%
[95% CI (45%–85%)] and mean RFS time was 133 months
[95% CI (97–170)]. For the patients with a normal or
increased PPR, the RFS estimate was 34% [95% CI (20%–
48%)] and median RFS time was 10 months [95% CI (0%–
Table 1 Patient characteristics
ITP patients [No. (%)] Healthy controls [No. (%)] p
No. of individuals 75 11 –
Age at time of platelet kinetic study (years)a 46 (16–89) 40 (25–60) 0.3
Male 34 (45%) 5 (45%) 1.0
Died during follow-up 16 (21%) – –
Platelets at diagnosis (×109/L) 8 (1–20) 150–350 –
Platelet kinetic parameters
Increased organ sequestration 57 (76%)b – –
Hepatic 12 (16%)b – –
Splenic 46 (61%)b – –
PPR (×109/day) 160 (2–4,670) 223 (100–355) 0.7
Decreased PPR (<100×109/day) 25 (33%) – –
Normal PPR (100–355×109/day) 36 (48%) – –
Increased PPR (>355×109/day) 14 (19%) – –
Mean platelet lifespan (days) 1 (0.1–6.5) 9.2 (7.4–11) <0.0001
Initial platelet recovery (%) 55 (27–76) 60 (45–88) 0.08
Treatment parameters
Follow-up time (months) 132 (13–348) – –
Prednisone
No. of patients 75 (100%) – –
Initial CR/PR to prednisone 63 (84%) – –
Durable CR/PR to prednisone 33 (44%) – –
Time to CR/PR on prednisone (months) 0.5 (0.1–3) – –
Duration of prednisone therapy (months) 6 (2–15) – –
Splenectomy
No. of patients 39 (52%) – –
Initial CR/PR postsplenectomy 35 (90%) c – –
Durable CR/PR postsplenectomy 29 (74%) c – –
Time to CR/PR postsplenectomy (months) 0.25 (0.03–3) – –
Dashes, not applicable; data are reported as median (range)
a Age at time of platelet kinetic study equals age at diagnosis for ITP patients
b One patient had both increased splenic and hepatic sequestration
c Percentage of patients that underwent splenectomy
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27%)] (mean 107 [95% CI (69–145)]). Characteristics of
the patient subgroups are depicted in Table 3. Among
patients with a normal or increased PPR, the mean platelet
lifespan was significantly shorter and splenic sequestration
was significantly more frequent.
Splenectomy Thirty-nine (93%) of the nonresponding
patients (n=42) underwent splenectomy. Characteristics of
nonresponding patients are shown in Table 2. Time to
splenectomy was 5 (1–82) months. Twenty-nine (74%)
patients reached a durable CR/PR to splenectomy only.
Table 2 Patient characteristics subdivided by durable response to prednisone
Durable CR/PR [No. (%)] No durable response [No. (%)] p
No. of patients 33 42 –
Age at diagnosis (years) 45 (21–89) 48 (16–74) 0.4
Male 19 (58%) 15 (36%) 0.1
Died during follow-up 9 (27%) 7 (17%) 0.4
Platelets at diagnosis (×109/L) 7 (1–20) 10 (1–20) 0.09
Platelet kinetic parameters
Increased hepatic sequestration 3 (9%) 9 (21%) 0.1
Increased splenic sequestration 19 (58%) 27 (64%) 0.3
PPR (×109/day) 120 (2–1,365) 171 (7–4,670) 0.1
Decreased PPRa 16 (48%) 9 (21%) 0.03
Mean platelet lifespan (days) 1.7 (0.1–6.5) 0.8 (0.1–4.3) 0.08
Initial platelet recovery (%) 55 (27–76) 54 (32–88) 0.7
Treatment parameters
Follow-up time, months 102 (13–293) 148 (27–348) 0.1
Prednisone
Initial CR/PR to prednisone 33 (100%) 30 (72%) 0.001
Time to CR/PR on prednisone (months) 0.5 (0.1–3) – –
Duration of prednisone therapy (months) 6 (2–15) 4 (1–33) 0.5
Splenectomy
No. of patientsb 0 39 (52%) –
Dashes, not applicable; data are reported as median (range)
a See Table 1 for definitions
b See Table 1 for treatment response characteristics
Fig. 1 RFS of ITP patients
following prednisone and fol-
lowing splenectomy
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Fig. 2 RFS of ITP patients
following prednisone therapy
by level of PPR
Table 3 Patient characteristics subdivided by PPR
PPR p
Decreased (<100×109/day) [No. (%)] Normal or increased (≥100×109/day) [No. (%)]
No. of patients 25 50 –
Age at diagnosis (years) 47 (17–85) 46 (16–89) 0.8
Male 9 (36%) 25 (50%) 0.3
Died during follow-up 5 (20%) 11 (22%) 1.0
Platelets at diagnosis (×109/L) 6 (1–20) 9 (1–18) 0.3
Platelet kinetic parameters
Increased hepatic sequestration 4 (16%) 9 (17%) 1.0
Increased splenic sequestration 9 (36%) 39 (79%) 0.001
PPR (×109/day) 27 (2–90) 230 (115–4,670) <0.0001
Mean platelet lifespan (days) 2.5 (0.4–6.5) 0.7 (0.1–4.8) <0.0001
Initial platelet recovery (%) 52 (27–76) 55 (32–88) 0.2
Treatment
Follow-up time (months) 83 (20–199) 160 (13–348) 0.001
Prednisone therapy
No. of patients 25 (100%) 50 (100%) –
Initial CR/PR to prednisone 23 (92%) 40 (80%) 0.3
Durable CR/PR to prednisone 16 (64%) 17 (34%) 0.03
Duration of prednisone (months) 5 (2–33) 4 (1–30) 0.7
Time to CR/PR on prednisone (months) 0.5 (0.1–1.5) 0.5 (0.1–3) 0.6
Splenectomy
No. of patients 8 (32%) 31 (62%) 0.03
Initial CR/PR postsplenectomy 7 (88%)a 28 (90%)a 1.0
Durable CR/PR postsplenectomy 6 (75%)a 23 (74%)a 1.0
Time to CR/PR postsplenectomy, months 0.25 (0.03–1) 0.25 (0.03–3) 0.9
Follow-up time postsplenectomy, months 94 (29–170) 157 (58–336) 0.03
Dashes, not applicable; data are reported as median (range)
a Percentage of patients that underwent splenectomy
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Figure 1 shows the RFS of the splenectomized patients
compared to the patients following prednisone therapy. RFS
estimate for the subgroup that underwent splenectomy was
74% [95% CI (59%–88%)] and the mean RFS time was
191 months [95% CI (157–225)]. For the nonresponders to
splenectomy, the time to splenectomy failure was 2 (0–94)
months. After splenectomy, four of 39 patients (10%)
obtained a CR/PR on cyclosporine, danazol or vincristin.
Six (8%) of 77 patients were refractory to any treatment.
There was no significant difference between responders and
nonresponders to splenectomy in patient age (p=1.0), sex
(p=0.6), platelet count at diagnosis (p=0.2), mean platelet
lifespan (p=0.3), PPR (p=0.4), and site of platelet
sequestration (spleen, p=0.7 and liver, p=0.1) and time to
splenectomy (p=1.0). These parameters were also not
significantly different between the groups with PPR
<100×109/day and ≥100×109/day.
Discussion
In the present study, patients with severe ITP were
investigated for associations between clinical character-
istics, thrombokinetic parameters, and the response to
treatment with prednisone or splenectomy. The results
demonstrate that patients with a decreased PPR had a
significantly higher durable CR or PR rate to prednisone
therapy than those with a normal or increased PPR. This
was also reflected in the significantly lower splenectomy
rate in the group of patients with a decreased PPR.
In ITP, therapy is generally not required when platelet
counts are above 20 to 30×109/L [12, 18]. Glucocorticoids
are usually the first choice of treatment for ITP. Initial
response rates of 50–90% have been reported depending on
the intensity and duration of therapy, but only 20–30% of
patients enter a prolonged remission, usually defined as
lasting more than 6 months after cessation of therapy [18–
22]. The overall long-term remission rate to prednisone in
the present study (44%) is higher than these reported
previously. Variations among the different studies with
regard to definitions of CR/PR, patient characteristics,
timing of splenectomy, and the pooling of different
remission rates may be responsible for these discrepancies.
Moreover, there is a large variation (3% to 50%) in reported
remission rates to glucocorticoids among the different
studies [12].
Several factors, including the duration of symptoms
before starting glucocorticoids, the speed of response, age,
sex, and initial platelet count, have been associated with a
favorable outcome of glucocorticoid treatment, but the
reproducibility of these associations among the different
studies has been low [22–27]. None of these factors
correlated with a response to prednisone in our analysis.
Although there was a high death rate in our patient cohort,
this was mainly due to the long follow-up time, and the
demographics are not different from ITP populations
studied previously.
To our knowledge, the predictive value of the PPR for
prednisone therapy in ITP has not been reported so far.
Previous studies have shown that prednisone improves the
platelet count in ITP primarily by increasing platelet
production [9, 10]. The present findings are consistent with
these results by showing that ITP patients with the lowest
PPR are the most likely to respond to prednisone in the
long term. In addition, patients with a decreased PPR
showed significantly less splenic sequestration and a
significantly longer mean platelet lifespan than patients
with a normal or increased PPR. These findings are
consistent with previous studies [8, 28–30] and further
underscore the heterogeneity of the disease. Thus, in
patients with a normal or elevated PPR, increased peripheral
destruction of platelets contributes relatively more to
thrombocytopenia than suppressed production, which is
reflected by a shorter mean platelet lifespan and a higher
rate of splenic uptake.
Since an enhanced platelet production would be the
normal compensatory response of the bone marrow to
thrombocytopenia due to peripheral destruction, ITP
patients with a normal PPR can also have an ineffective
platelet production. In autoimmune hemolytic anemia, the
compensatory reaction is much more pronounced, except
when circulating antibodies are directed to normoblasts
[31]. Previous studies have shown that, in the majority of
ITP patients, the PPR is either reduced or normal [28, 30,
32–36]. Additional support for a suppressed platelet
production in ITP comes from in vitro studies showing
that megakaryocyte production and maturation can be
inhibited by antiplatelet antibodies [1, 2, 37]. Similar in
vitro cultured megakaryocytes in the presence of ITP
plasma show features compatible with premature cell death
[3]. The variability in PPR among different individuals is
therefore likely to be related to the degree of autoantibody
binding to megakaryocyte antigens. Other mechanisms,
including capacity and function of the reticuloendothelial
system, the degree of autoantibody-induced activation of
complement, and T-lymphocyte-mediated cytotoxity may
also play a role [1]. We did not observe a difference in
response rates to prednisone between patients with normal
and increased PPRs. This might be due to the small number
of patients studied.
Different mechanisms have been proposed for explaining
the beneficial effects of prednisone on the reduced platelet
production, including impairment of autoantibody binding
to megakaryocytes [9, 38, 39], an altered Fcγ-receptor-
mediated immune clearance [40, 41], and a reduction of
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antibody production due to a lympholytic effect [42–44]. In
addition, a reduction of premature cell death of ITP
megakaryocytes has been observed during in vivo prednisone
therapy [3].
That reduced platelet production is an important mech-
anism in ITP in vivo is also supported by recent studies
with the novel thrombopoiesis-stimulating agents, such as
thrombopoietin mimetic AMG-531. Short-term use of
AMG-531 increased platelet counts in about 75% of ITP
patients [45], whereas preliminary results show sustained
platelet responses in about 50% of patients [46]. It is
conceivable that these agents primarily promote the PPR
without modulating the platelet half life. In summary, patients
with severe ITP and a decreased PPR demonstrate an
approximately two-times-higher long-term remission rate to
prednisone and are significantly less likely to need splenec-
tomy than ITP patients with a normal or increased PPR.
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